Novo’s obesity drug gets TGA tick

By Megan Brodie 4 years ago | In Companies, Regulatory
  • 4 years ago

5 September 2022 The TGA has finally approved Novo Nordisk’s semaglutide WEGOVY as a treatment…

This is subscriber-only content. Please login to continue reading.

Recent News

Top Reads